Although the primary endpoint of this phase 2/3 study was not met, broader analyses suggest potential trends towards a benefit of idursulfase-IT treatment in stabilizing or slowing the progression of cognitive impairment in some children with neuronopathic MPS II. Here, IDS is linked to mucopolysaccharidosis type 2.